文献速递泌尿生殖腹部MR

接受与未接受肌内注射胰高血糖素患者前列腺MRI T2加权图像质量评估

Assessment of T2-weighted Image Quality at Prostate MRI in Patients with and Those without Intramuscular Injection of Glucagon.
PubMed 文献 · Radiol Imaging Cancer · 2023-01-01

该单中心回顾性研究分析2495例前列腺多参数MRI报告及120例轴位T2加权图像半定量评估,比较肌内注射胰高血糖素与未注射组的图像质量;结果显示注射胰高血糖素并未改善T2加权图像整体质量,仅在直肠和淋巴结评估时更易获高评分,PI-RADS病灶检出及靶向活检Gleason评分无差异。

要点

  • 肌内注射胰高血糖素未改善前列腺MRI T2加权图像整体质量。
  • 仅在评估直肠和淋巴结时,注射胰高血糖素组更易获4或5分高评分。
  • 两组PI-RADS病灶检出及靶向活检Gleason评分无差异。

核心结论

  • 肌内注射胰高血糖素未改善前列腺MRI检查的T2加权图像质量,且PI-RADS评分和活检结果与未注射组相似。

研究设计与样本

  • 符合《健康保险流通与责任法案》的单中心回顾性研究,分析2013年9月至2019年9月间3960次前列腺多参数MRI检查报告(排除后2495次),并对2015年5月至2016年2月间120次连续检查的轴位T2加权图像进行半定量评估。

关键影像表现/征象

  • 三位经验丰富的放射科医生在不知是否注射胰高血糖素的情况下,采用五点Likert量表(5=无运动或模糊)评估整体图像质量、解剖结构 delineation(前列腺包膜、直肠、淋巴结)及良性前列腺增生结节识别。
  • 注射胰高血糖素组与未注射组在MRI报告提及模糊或运动的数量上相似(P=0.82)。
  • 仅在评估直肠(P=0.001)和淋巴结(P=0.01)时,注射胰高血糖素组图像更可能获得4或5分高评分。
  • 在评估前列腺包膜、良性前列腺增生结节或整体图像质量时,两组无显著差异。

诊断标准与关键数值

  • 采用五点Likert量表评估图像质量(5=无运动或模糊)。
  • 注射胰高血糖素组与未注射组在MRI报告提及模糊或运动的数量相似(P=0.82)。
  • 注射胰高血糖素组在直肠评估中更可能获高评分(P=0.001),在淋巴结评估中更可能获高评分(P=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To assess whether administration of intramuscular (IM) glucagon improves T2-weighted image quality at multiparametric MRI (mpMRI) of the prostate. Materials and Methods In this Health Insurance Portability and Accountability Act-compliant single-center study, the authors retrospectively analyzed radiology reports from 3960 mpMRI examinations (2495 after exclusions) performed between September 2013 and September 2019 and performed outcome comparisons and semiquantitative image assessment of axial T2-weighted images from 120 consecutive mpMRI examinations performed between May 2015 and February 2016. Three experienced radiologists blinded to administration of IM glucagon assessed images using a five-point Likert scale (5 = no motion or blur) for overall image quality, anatomic delineation (prostate capsule, rectum, and lymph nodes), and identification of benign prostatic hyperplasia nodules. Wilcoxon rank sum and χ2 tests were used to assess quantitative parameters. Results The number of mpMRI radiology reports (599 examinations performed with glucagon; 1896, without glucagon) mentioning blur or motion were similar between groups (P = .82). Regression analysis of semiquantitative image quality assessments of T2-weighted images from mpMRI examinations (60 performed with glucagon; 60, without glucagon) demonstrated that images with glucagon were more likely to receive higher scores (4 or 5 rating) than those without glucagon only when the rectum (P = .001) and lymph nodes (P = .01) were evaluated, not when the prostatic capsule, benign prostatic hyperplasia nodules, or overall image quality was evaluated. No evidence of differences was found in identified Prostate Imaging Reporting and Data System (PI-RADS) lesions or targeted-biopsy Gleason scores. Conclusion Administration of IM glucagon did not improve T2-weighted image quality in prostate MRI examinations and showed similar PI-RADS scores and biopsy yields compared with examinations without glucagon. Keywords: MRI, Genital/Reproductive, Urinary, Prostate, Oncology, Observer Performance © RSNA, 2023 Online supplemental material is available for this article. See also commentary by Eberhardt in this issue.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Sundaram KM, Rosenberg J, Syed AB, et al. Assessment of T2-weighted Image Quality at Prostate MRI in Patients with and Those without Intramuscular Injection of Glucagon. Radiol Imaging Cancer. 2023. PMID: 37171269. doi:10.1148/rycan.220070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。